We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi and Regeneron’s Dupixent (dupilumab) continues its march against a host of chronic inflammatory diseases, posting positive phase 3 data in children with eosinophilic esophagitis, a chronic inflammation of the esophagus associated with acid reflux, gastrointestinal problems, difficulty eating and failure to thrive. Read More
More encouraging news about potential hemophilia therapeutics emerged this week, with Sanofi announcing “unprecedented” phase 3 data on efanesoctocog alfa, a bioengineered clotting factor, and fitusiran, an RNA therapeutic that lowers antithrombin. Read More
Xeljanz, a Janus kinase inhibitor, is FDA-approved for several indications, including for patients with moderate-to-severe active ulcerative colitis. Read More
Novo Nordisk made some headlines in London this week, presenting positive data from hemophilia therapeutics trials at the International Society of Thrombosis and Hemostasis Annual Congress. Read More
Skyhawk Therapeutics, a three-year-old biotech spawned by entrepreneur, inventor and documentary filmmaker Bill Haney, has inked a new deal with Sanofi that has the two companies working together on challenging oncology and immunology targets. Read More
Faced with a barrage of pleas from both clinicians and patients, the FDA will hold a second expert panel hearing on Amylyx’s AMX0035, a drug intended to treat amyotrophic lateral sclerosis (ALS). Read More
Uveitis — an inflammation of the middle layer of the eye — in treated patients has prompted FDA to halt enrollment in Nuvation Bio’s phase 1/2 dose-escalation study of NUV-422, a checkpoint inhibitor under investigation for a wide variety of solid tumors. Read More